Craigavon-based global contract pharmaceutical development and manufacturing organisation Almac Group has reported its highest ever revenue, profit, and employee numbers for the financial year ended 30 September 2025, with revenue reaching £1.1bn (€1.3bn) and pre-tax profit rising 16% to £139m (€166m).

The Belfast Telegraph reported that revenue grew by £71.9m (€86m), a 7% increase on the prior year, reflecting continued demand across Almac's global pharmaceutical and biotech client base, while the group's workforce expanded to more than 7,900 people worldwide.

Almac, which is privately owned and headquartered in Craigavon, Co. Armagh, reinvests all profit back into the business. The latest results form part of the group's ongoing £400m-plus global capital investment programme, now in its fifth year, which has included the development of a Centre of Excellence for diagnostic manufacturing and a 100,000 sq ft state-of-the-art pharmaceutical manufacturing facility.

Alan Armstrong, chairman and CEO of Almac Group, said: "These results reflect another successful year for Almac and demonstrate the resilience of our long-term growth strategy in a changing global environment. As a privately owned company, we are proud to reinvest our profits to support our global clients, drive innovation and expand our capabilities. None of this would be possible without the exceptional commitment of our people across the globe."

Almac operates across pharmaceutical development, manufacturing, testing, and distribution, and was involved during the financial year in the development of drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy, and neurology.

The group said continued investment in infrastructure and talent would remain central to its strategy as it looks to further expand capacity and strengthen its position as a leading global contract development and manufacturing organisation.

Read the full report on Almac Group's record financial results.